68Ga-BCMA PET/CT in Multiple Myeloma

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking University First Hospital

About this trial

This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.

Eligibility criteria

Qualifiers

patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse;

patients with confirmed symptomatic MM;

ability to understand and voluntarily sign written informed consent;

ability to comply with study procedures;

Disqualifiers

pregnancy or lactation;

inability to comprehend study procedures or cooperate with protocol requirements;

any other condition judged by the investigator to potentially interfere with study participation.

Trial design

Treatments tested in this trial

  • 68Ga-BCMA PET/CT

Treatment groups

300 Participants
are divided into 1 treatment group

Sponsors and collaborators

Peking University First Hospital

Lead sponsor

The First Hospital of Jilin University

Collaborator

The Second Hospital of Hebei Medical University

Collaborator

Beijing Anzhen Hospital

Collaborator

Beijing Tsinghua Changgeng Hospital

Collaborator